drugset / Trial / NCT06731868
Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This is a multicenter, randomized, double-blind, placebo-controlled parallel-group trial to evaluate the safety, tolerability, preliminary efficacy and PK characteristics of multiple doses of LPM3770164 sustained-release tablets in TD patients.
Timeline
- Start
- 2025-01-14
- Primary completion
- 2025-10-31
- Completion
- 2025-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | LPM3770164 | Unknown | 5 mg | Oral |
| Subject | LPM3770164 | Unknown | 10 mg | Oral |
| Subject | LPM3770164 | Unknown | 20 mg | Oral |